Literature DB >> 22943386

Seventeen-years overview of breast cancer inside and outside screening in Denmark.

Laia Domingo1, Katja Kemp Jacobsen, My von Euler-Chelpin, Ilse Vejborg, Walter Schwartz, Maria Sala, Elsebeth Lynge.   

Abstract

BACKGROUND: Long-term data on breast cancer detection in mammography screening programs are warranted to better understand the mechanisms by which screening changes the breast cancer pattern in the population. We aimed to analyze 17 years of breast cancer detection rates inside and outside screening in two Danish regions, emphasizing the influence of organizational differences of screening programs on the outcomes.
MATERIAL AND METHODS: We used data from two long-standing population-based mammography screening programs, Copenhagen and Fyn, in Denmark. Both programs offered biennial screening to women aged 50-69 years. We identified targeted, eligible, invited and participating women. We calculated screening detection and interval cancer rates for participants, and breast cancer incidence in non-screened women (= targeted women excluding participants) by biennial invitation rounds. Tumor characteristics were tabulated for each of the three groups of cancers.
RESULTS: Start of screening resulted in a prevalence peak in participants, followed by a decrease to a fairly stable detection rate in subsequent invitation rounds. A similar pattern was found for breast cancer incidence in non-screened women. In Fyn, non-screened women even had a higher rate than screening participants during the first three invitation rounds. The interval cancer rate was lower in Copenhagen than in Fyn, with an increase over time in Copenhagen, but not in Fyn. Screen-detected cancers showed tumor features related with a better prognosis than tumors detected otherwise, as more than 80% were smaller than 20 mm and estrogen receptor positive.
CONCLUSION: Data from two long-standing population-based screening programs in Denmark illustrated that even if background breast cancer incidence and organization were rather similar, performance indicators of screening could be strongly influenced by inclusion criteria and participation rates. Detection rates should be interpreted with caution as they may be biased by selection into the screening population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22943386     DOI: 10.3109/0284186X.2012.698750

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  6 in total

1.  Comparing sensitivity and specificity of screening mammography in the United States and Denmark.

Authors:  Katja Kemp Jacobsen; Ellen S O'Meara; Dustin Key; Diana S M Buist; Karla Kerlikowske; Ilse Vejborg; Brian L Sprague; Elsebeth Lynge; My von Euler-Chelpin
Journal:  Int J Cancer       Date:  2015-06-01       Impact factor: 7.396

2.  Body mass index and participation in organized mammographic screening: a prospective cohort study.

Authors:  Sophie Sell Hellmann; Sisse Helle Njor; Elsebeth Lynge; My von Euler-Chelpin; Anja Olsen; Anne Tjønneland; Ilse Vejborg; Zorana Jovanovic Andersen
Journal:  BMC Cancer       Date:  2015-04-17       Impact factor: 4.430

3.  Breast cancer in European Union: an update of screening programmes as of March 2014 (review).

Authors:  E Altobelli; A Lattanzi
Journal:  Int J Oncol       Date:  2014-09-01       Impact factor: 5.650

4.  DNA Methylation Heterogeneity Patterns in Breast Cancer Cell Lines.

Authors:  Sunny Tian; Karina Bertelsmann; Linda Yu; Shuying Sun
Journal:  Cancer Inform       Date:  2016-09-07

5.  Impact of invitation schemes on breast cancer screening coverage: A cohort study from Copenhagen, Denmark.

Authors:  Katja Kemp Jacobsen; My von Euler Chelpin; Ilse Vejborg; Elsebeth Lynge
Journal:  J Med Screen       Date:  2016-06-23       Impact factor: 2.136

6.  Breast cancer mortality and overdiagnosis after implementation of population-based screening in Denmark.

Authors:  Elsebeth Lynge; Anna-Belle Beau; My von Euler-Chelpin; George Napolitano; Sisse Njor; Anne Helene Olsen; Walter Schwartz; Ilse Vejborg
Journal:  Breast Cancer Res Treat       Date:  2020-08-30       Impact factor: 4.872

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.